Introduction {#sec1-1}
============

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, especially in Southeast Asia, where chronic hepatitis B infection has a high prevalence (International Agency for Research on Cancer, 1987; Munoz et al., 1989; Bosch et al., 1991; Okuda et al., 1992). In the era of regular surveillance programs for all at-risk populations, the prevalence of newly detected small tumors less than 2 cm in diameter increased to 30 % in Japan, whereas the prevalence was less than 5 % in the early nineties in Europe (European Association For The Study Of The Liver, 2012). Nevertheless, the diagnosis of small HCC (1-2 cm) could be difficult because of the lack of typical vascular patterns on dynamic imaging (Bosch et al., 1991; Okuda et al., 1992; Bosch et al., 1999; Chen et al., 2010), and the diagnosis often requires the use of more than one imaging modality (Bruix et al., 2011; Forner et al., 2012).

Recently published guidelines by the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) proposed a diagnostic algorithm for HCC nodules 1-2 cm in diameter (Bruix et al., 2011; European Association For The Study Of The Liver, 2012). The guidelines included the detection of arterial hypervascularity and portal or delayed venous washout in only one dynamic radiological procedure, either multidetector computed tomography (MDCT) or dynamic magnetic resonance imaging (MRI). When these features are not present, either a second contrast-enhanced imaging study or image-guided biopsy is recommended.

The most suitable initial imaging technique (CT or MRI) and the sequential diagnostic strategy that gives the best diagnostic accuracy in small HCC are still in consideration due to a variety of diagnostic sensitivities based on previous studies (Rode et al., 2001; Bolondi et al., 2005; Forner et al., 2008; Yu et al., 2008; Sangiovanni et al., 2010; Kim et al., 2011; Yu et al., 2011; Serste et al., 2012; Park et al., 2014). One study found that the best diagnostic strategy was a sequential imaging study (inconclusive MRI result followed by CT scan) with a sensitivity of 74 % instead of a second concomitant imaging study (combination of CT and MRI) (Khalili et al., 2011). However, one could argue that such a strategy would leave some underdiagnosed HCC in 26 % of the cases and was not cost effective (Sangiovanni et al., 2010).

The aim of this study was to compare the sensitivity and agreement between multidetector computed tomography (MDCT) and dynamic magnetic resonance imaging (MRI) for the diagnosis of small hepatocellular carcinoma (1-2 cm).

Material and Methods {#sec1-2}
====================

Study population {#sec2-1}
----------------

This study was a retrospective analysis that focused on patients under the care of the Department of Medicine, Faculty of Medicine at Songklanagarind Hospital, which is the largest tertiary referral university hospital in the southern part of Thailand, between 1 March 2008 and 1 March 2014. The study was approved by the Institutional Review Board of the Faculty of Medicine, Prince of Songkla University. The diagnosis of cirrhosis was based on either histopathology or a combination of physical examination, laboratory tests, and imaging data. The diagnosis of HCC was based on histopathology or the 2005 AASLD diagnostic criteria, in which a coincidental typical vascular pattern (i.e. enhancement during the hepatic arterial phase and washout during the hepatic venous and/or delayed phase) is observed with both imaging techniques (CT and MRI).

The patient inclusion criteria were as follows: 1) diameter of HCC between 1 and 2 cm; 2) both CT and MRI were available and showed satisfactory nodule visibility for review; 3) patients at risk (i.e. cirrhosis from any cause); and 4) age \> 18 years. The demographic and clinical characteristics, including age, gender, etiology of cirrhosis, level of serum alpha-fetoprotein and baseline liver function laboratory results were documented for each patient.

Imaging technique {#sec2-2}
-----------------

MDCT

Helical multidetector quadruple-phase CT was performed using a 64-section scanner (Philips Brilliance, Royal Philips Electronics, Netherlands) with a collimation of 64 x 0.625 mm. Images with an effective section thickness of 3.0 mm were reconstructed every 2 mm. The contrast-enhanced liver images were obtained after a bolus intravenous injection of 2.0 mL/kg of a nonionic contrast agent (Iomeron 350, Bracco or Ultravist 370, Bayer) at a rate of 3-3.5 mL/s through an 18-20 gauge intravenous catheter, followed by a flush of 50 mL of saline administered at the same injection site. The start of the scans was triggered according to a test tracker positioned over the abdominal aorta. The scans started 18 s (late arterial phase) after reaching the trigger threshold (150 HU) in the aorta, 70 s (portal venous phase) and 180 s (delayed phase).

MRI

MRI was performed with 1.5 T scanners (Vision, Siemens, Germany \[from November 1995 to June 2012\] and Ingenia, Philips, Netherlands \[from July 2012\]) using a body phased-array multicoil for signal detection. All patients underwent transverse T1-weighted and T2-weighted MRI and multiphasic contrast enhanced dynamic 3-dimensional MRI of the whole liver with fat suppression.

The imaging protocol included axial pre-contrast images acquired with a T2-weighted fast-spin echo sequence (TR/TE = 4009/80 ms, section thickness 5--7 mm) and T1-weighted in-phase and out-of-phase gradient-recalled-echo (GRE) sequences (TR/TE = 6.5/2.3-4.6 ms, section thickness, 2--3 mm). Dynamic studies were performed with three-dimensional T1-weighted GRE sequence (Vision, Siemens: TR/TE = 5.2/2.6 ms; Flip angle 20°; section thickness 3 mm and Ingenia, Philips: TR/TE = 3.9/1.85 ms; Flip angle 10°; section thickness 2-3 mm). The contrast agents were varyingly administered according time deference and included Gadovist® Bayer Germany, gadopentetate dimeglumine 0.5 mmol/mL; Magnevist® Bayer Germany or MultiHance® Bracco Italy, gadoteric acid 0.5 mmol/mL; Dotarem® Guerbet France, and gadoterate meglumine 0.5 mmol/mL. The contrast was injected manually at a dose of 0.2 mL/kg body weight at a rate of 2 mL/s through a 20-23-gauge intravenous catheter. The arterial phase, portal venous and delayed venous phase images were acquired at 30, 60 and 180 s from the start of contrast injection, respectively. The additional hepatobiliary phase was not used in our study.

Imaging analysis {#sec2-4}
----------------

The images were read blindly by a board certified radiologist (T.T.) with more than 5 years of experience in liver imaging who was unaware of the patient's profile, treatment, and other contrast techniques. For each imaging study, the number, size, location, and vascular pattern of the lesions were detected and analyzed.

Vascular pattern was qualified as "conclusive" for HCC if contrast washout occurred, defined as the presence of hypervascularity during the arterial phase followed up by a hypodense/hypointense appearance in later phases defining washout. Nodules in which an enhancement was found during the arterial phase with- out washout were qualified as "suspicious."

The conclusive radiological pattern of HCC for both imaging techniques (CT or MRI) was arterial hypervascularization followed by portal/venous or delay contrast washout of the nodule. Arterial hypervascularization was seen as increased contrast enhancement of the nodule (hyperdensity on CT and hyperintensity on MRI) taking place during the arterial phase of the examination as compared with the surrounding liver parenchyma. Portal/venous contrast washout was seen as a hypoenhanced pattern of the nodule (hypodensity on CT and hypointensity on MRI) with respect to the surrounding liver parenchyma taking place during the portal/venous or delay phase. Nodules with only arterial enhancement without venous washout were classified as suspicious findings. The remaining nodules with negative arterial enhancement were defined as non-diagnostic nodules. For MRI, T1-weighted, T2-weighted and DWI data were not included for the diagnostic vascular analysis.

Liver histology {#sec2-5}
---------------

Ultrasound-guided biopsy was performed using Quick-Core® biopsy needles before January 2014 (COOK Medical, Bloomington, USA) and semi-automatic biopsy needles from January 2014 (GEOTEK Medical, Ankara, Turkey). The specimens were routinely processed and stained with hematoxylin and eosin by the Masson trichrome method.

Statistical analysis {#sec2-6}
--------------------

The sensitivity and inter-modality agreement were calculated for the nodules that underwent both MDCT and dynamic MRI. Cohen's kappa statistic (k) for the inter-modality agreement was calculated. Kappa values less than 0.2 indicated positive but poor agreement, 0.2--0.4 indicated fair agreement, 0.4--0.6 indicated moderate agreement, 0.6--0.8 indicated good agreement, and greater than 0.81 indicated excellent agreement. Associations between the continuous and categorical variables were analyzed using the Mann Whitney U-test and the chi-square test or Fisher's exact test, respectively. Statistical significance was defined as a p value less than 0.05. The statistical analyses were performed using the SPSS 11.5 software package (SPSS Inc., Chicago, IL, USA).

Results {#sec1-3}
=======

During the study period, 67 patients from the data registry met the criteria for diagnosis of a 1-2 cm HCC. The thirty-one cases were excluded according to utility of single imaging for diagnosis and proceeding to definite treatment. Thirty-six small HCC patients underwent both CT and MRI, and nine were excluded because of poor MRI quality. We enrolled 27 consecutive patients, including 21 men and 6 women with a mean age of 61 years (range, 37--82 years). The mean size of the 27 HCC nodules was 16 mm (range, 10-20 mm) and consisted of 14 pathologically confirmed nodules. [Figure 1](#F1){ref-type="fig"} illustrates the outline of the study enrollment.

![Schematic Outline of the Study Process](APJCP-17-4805-g001){#F1}

Cirrhosis was diagnosed in all patients. Underlying liver cirrhosis was associated with viral hepatitis B in 11 patients, viral hepatitis C in 4 patients, hepatitis B virus and hepatitis C virus co-infection in 1 patient, and alcoholic cirrhosis in 8 patients. The other causes of cirrhosis consisted of cryptogenic cirrhosis in 2 patients and autoimmune hepatitis in 1 patient. Based on the Child-Pugh classification, 22 patients were classified as Child-Pugh class A, and the remaining 5 patients were class B. The demographic, baseline clinical, and biochemical characteristics of the study patients are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Baseline Characteristics of All Patients

                                                                         All                  Histopathology
  ---------------------------------------------------------------------- -------------------- --------------------
  Number of nodules                                                      27.0                 14
  Age mean ± SD (range)                                                  61 ± 11.7 (37-82)    63 ± 10.1 (49-82)
  Sex, Male (%)                                                          21.0 (77.8)          9.0 (64.3)
  Population at risk of Cirrhosis (%)                                    27.0 (100.0)         14.0 (100.0)
  Etiology of cirrhosis (%)                                                                   
   HBV                                                                   11.0 (40.7)          5.0 (35.7)
   HCV with co-infection                                                 5.0 (18.5)           3.0 (21.4)
   Alcohol                                                               8.0 (29.6)           4.0 (28.6)
   Others^[a](#t1f1){ref-type="table-fn"}^                               3.0 (11.1)           2.0 (14.3)
  Child-Pugh class (%)                                                                        
   A                                                                     22.0 (81.5)          12.0 (85.7)
   B                                                                     5.0 (18.5)           2.0 (14.3)
  Median AFP, ng/mL (range)                                              19.0 (2.0-140.0)     14.0 (2.0-86.0)
  USG surveillance (%)                                                   25.0 (92.6)          13.0 (92.9)
  Method for pathologic confirmation (%)                                                      
   FNB                                                                   12.0 (44.4)          12.0 (85.7)
   Surgery                                                               2.0 (7.4)            2.0 (14.3)
  Treatment (%)                                                                               
   Intervention^[b](#t1f2){ref-type="table-fn"}^                         25.0 (92.6)          12.0 (85.7)
   Surgery                                                               2.0 (7.4)            2.0 (14.3)
  Laboratory investigation (range)                                                            
   INR                                                                   1.1 (0.9-1.5)        1.1 (0.9-1.3)
   Platelet count (103/µl)                                               103.0 (30.0-185.0)   103.0 (30.0-185.0)
   TB (mg/dl)                                                            1.2 (0.3-11.1)       1.2 (0.4-5.1)
   Albumin (g/dl)                                                        3.7 (2.4-4.9)        3.8 (2.8-4.8)
   AST (U/L)                                                             51.0 (22.0-120.0)    44.0 (22.0-120.0)
   ALT (U/L)                                                             34.0 (13.0-95.0)     29.0 (14.0-59.0)
   ALP (U/L)                                                             109.0 (55.0-220.0)   113.0 (60.0-163.0)
   Cr (mg/dl)                                                            1.0 (0.6-1.8)        1.0 (0.6-1.8)
  Duration to diagnosis^[c](#t1f3){ref-type="table-fn"}^, days (range)   59.0 (1.0-357.0)     60.0 (16.0-273.0)
  Mean size of the maximal diameter of nodule, mm (range)                16.0 (10.0-20.0)     17.0 (12.0-20.0)

Consisted of cryptogenic (N = 2, 7.4 %), autoimmune hepatitis (N = 1, 1.7 %);

Consisted of PEI (N = 17, 63 %), RFA (N = 1, 3.7 %), TOCE (N = 7, 25.9 %);

The median of the data set.

There were no significant differences in the baseline clinical or biochemical characteristics between the histopathologically and non-histopathologically diagnosed groups. The median duration between the first and second imaging sessions was 32 days (min-max, 4-125 days). The frequency vascular pattern of CT and MRI is shown in [Table 2](#T2){ref-type="table"}. On CT, the nodules were of the conclusive pattern (i.e. defined as arterial enhancement and washout during the portal or delayed phases) in 21 of 27 cases, whereas the nodules were of the conclusive pattern in 14 of 27 cases on MRI. Suspicious patterns of nodules on CT and MRI were observed in 11 % and 22 % of cases, respectively. According to the signal intensity on standard MRI sequences, hyperintensity and hypointensity of nodules on T1-weighted images occurred in 41 % and 41 %, respectively, whereas they were 70 % and 11 % on T2-weighted images, respectively.

###### 

Frequency of Vascular Pattern between Types of Imaging for 1-2 cm HCC

                                                  All nodules N (%)
  --------------- ------------------------------- --------------------
  MDCT (N = 27)   Conclusive                      21 (78)
                  Suspicious                      3 (11)
                  Non-diagnostic                  3 (11)
  MRI (N = 27)    Conclusive                      14 (52)
                  Suspicious                      6 (22)
                  Non-diagnostic                  7 (26)
                  T1W (hyper/hypo/isointensity)   11/11/5 (41/41/18)
                  T2W (hyper/hypo/isointensity)   19/3/5 (70/11/19)

Conclusive, refers to arterial enhancement and washout during portal or delayed phases; Suspicious, refers to arterial enhancement without washout during portal or delayed phases; Non-diagnostic, refers to no arterial enhancement.

Conclusive findings for the diagnosis of HCC were detected in both imaging modalities in 56 % (15/27) of the HCC nodules. The inter-modality agreement for the assessment of a conclusive or inconclusive tumor enhancement pattern was 67 % (18/27) (k = 0.319, p = 0.05). Arterial enhancement on both imaging techniques was detected in 70.4 % (19/27) of the HCC nodules. Agreement for the detection of the presence or absence of arterial enhancement was 78 % (21/27) (k = 0.289, p = 0.088). A tumor washout pattern on both imaging techniques was detected in 48 % (13/27) of the HCC nodules. Agreement for the detection of the presence or absence of portovenous/delay washout was 59 % (16/27) (k = 0.163, p = 0.244). The agreement and disagreement of specific HCC enhancement patterns of CT and MRI are shown in [Table 3](#T3){ref-type="table"}.

###### 

Agreement and Disagreement between Types of Imaging for 1-2 cm HCC

                      Arterial enhancement   Portovenous/Delay phase washout
  ------------------- ---------------------- ---------------------------------
  Agreement                                  
   MDCT (C) MRI (C)   19 (70.4)              13 (48.1)
   MDCT (I) MRI (I)   2 (7.4)                3 (11.1)
  Disagreement                               
   MDCT (C) MRI (I)   5 (18.5)               10 (37.0)
   MDCT (I) MRI (C)   1 (3.7)                1 (3.7)
  Kappa Value         0.289                  0.163
  P value             0.088                  0.244

Note, Numbers are the number of lesions (%); (C), Presence of arterial enhancement and presence of washout; conclusive enhancement pattern; (I), Presence of arterial enhancement without washout or absence of arterial enhancement; inconclusive enhancement pattern.

The diagnostic sensitivity of CT and MRI is shown in [Table 4](#T4){ref-type="table"}. The sensitivity to diagnose HCC was 78 % on CT and 52% on MRI (p = 0.04), respectively. In the histopathology proven group, the CT scan also had a higher sensitivity than MRI (86 % versus 43 %, p = 0.02). The sensitivity of a conclusive pattern to diagnose HCC on at least one of the two imaging studies was 81 %, whereas the sensitivity was 48 % on both imaging studies (p = 0.01).

###### 

Sensitivity between Types of Imaging for Diagnosis of 1-2 cm HCC

                 All nodules underwent both CT and MRI (N = 27)          Histopathology group (N = 14)   
  -------------- ------------------------------------------------ ------ ------------------------------- ------
  MDCT           78                                                      86                              
  MRI            52                                               0.04   43                              0.02
  MDCT or MRI    81                                                      86                              
  MDCT and MRI   48                                               0.01   43                              0.02

Conclusive (typical), refers to arterial enhancement and washout during portal or delayed phases; Inconclusive (atypical), refers to arterial enhancement without washout during portal or delayed phases or no arterial enhancement.

In patients with inconclusive CT results, proceeding to MRI gave only an additional 3.7 % sensitivity to reach a diagnosis. In cases of inconclusive MRI results, a further CT gave an additional 29.6 % sensitivity to reach a diagnosis.

Discussion {#sec1-4}
==========

Our results confirmed that CT or MRI yielded a better sensitivity rate of 81 % for HCC diagnosis of 1-2 cm nodules compared with a combination of CT and MRI, in which case the sensitivity dropped to 48 %. This finding supported previous studies (Forner et al., 2008; Sangiovanni et al., 2010; Leoni et al., 2010; Khalili et al., 2011; Serste et al., 2012; Furlan et al., 2012) that reported that the sensitivity of coincidental conclusive findings in both imaging techniques was less than that of a single imaging technique.

The study results showed fair agreement (67 % (k = 0.319)) between the CT and MRI findings for an illustration of typical tumor enhancement pattern of 1-2 cm HCC nodules. This finding is consistent with previous studies (Leoni et al., 2010; Sangiovanni et al., 2010) found that the tumor enhancement pattern (typical or atypical) was concomitantly detected in only 64 % and 59 % of 10--20 mm HCC nodules, respectively. However, another recent study (Furlan et al., 2012) showed good agreement between CT and MRI (81 %, k = 0.607).

Our study showed a discordance between CT and MRI imaging because the portovenous/delay washout (59 %, k = 0.16) appeared to be more than that of arterial enhancement (78 %, k = 0.29). The resolution of tumor washout was affected by many factors, such as the degree of (Jang et al., 2007; Liu et al., 2007; Park et al., 2014) histological differentiation, the timing sequence of the tumor washout phase, the degree of fibrotic liver parenchyma (Vignaux et al., 1999; Yu et al., 2008), contrast agent diffusion, and fat in the lesions (Wilson et al., 2007; Khan et al., 2010).

Based on a single modality for HCC diagnosis of 1-2 cm nodules, our results showed that CT had a higher sensitivity than MRI (78 % versus 52 %), which was different from the findings of some previous studies (Leoni et al., 2010; Hwang et al., 2012; Serste et al., 2012; Park et al., 2014) that reported a tendency of MRI to have a higher sensitivity than a CT scan in the diagnosis of small HCC less than 2 cm in diameter (44-74 % on CT and 42-82 % on MRI) (Rode et al., 2001; Bolondi et al., 2005; Forner et al., 2008; Yu et al., 2008; Sangiovanni et al., 2010; Kim et al., 2011; Yu et al., 2011; Serste et al., 2012; Park et al., 2014). The recent study (Sangiovanni et al., 2010) showed that the sensitivity and accuracy of CT scan for HCC diagnosis of 1-2 cm nodules was equal to MRI (44 % versus 44 % and 65 % versus 66 %).

The explanations for the higher sensitivity of the CT scan than MRI in our study might be because more patient cooperation is needed in the MRI room than in a CT scan to achieve a high resolution and the fewest number of imaging artifacts. Although there were no reported studies on the correlation between the sensitivity of liver MRI and patient cooperation, two studies of coronary MRI suggested that poor patient cooperation played an important role in poor imaging resolution and low sensitivity of the technique (Danias et al., 1998; Nikolaou et al., 2002). Furthermore, the utility of different contrast agents across the studies' time was the factor that might affect the result. A recent meta-analysis (Kierans et al., 2016) showed that the use of gadoxetate disodium as a MRI contrast agent was independently associated with a higher sensitivity of HCC diagnosis in small nodules. Finally, most of the studies in the meta-analysis (Kierans et al., 2016) that showed a higher sensitivity of MRI performed hepatobiliary phase imaging, which could enhance the test sensitivity but also adds expenses to the test; therefore, the cost effectiveness analysis of first-line imaging for diagnosis of small HCC should be examined in a future study.

Adding a sequential MRI to the CT scan only resulted in a diagnosis in an additional 3.7 %. We suggest proceeding with a liver biopsy if the CT shows an inconclusive result after seriously considering the procedure risks.

Our study had several limitations. First, the study was performed in a single center, and its retrospective nature possibly introduced a selection bias. Second, not all tumors were pathologically confirmed. Nevertheless, we attempted to confute this effect by a subgroup analysis performed only in the histopathology group, which still showed that CT had a higher sensitivity than MRI. Moreover, acquiring pathological confirmation of all hepatic nodules less than 2 cm in size in a cirrhotic liver would not be practical in clinical settings. Third, we excluded more than 50 % of patients who underwent single imaging and proceeded to HCC treatment; however, we also analyzed the sensitivity of CT and MRI in this group. The results confirmed a higher sensitivity for CT than MRI. Finally, our study included only HCC; therefore, there might have been a potential bias for the radiologist when interpreting the CT and MRI findings.

Multiphasic CT has a higher sensitivity than MRI for the diagnosis of small HCC less than 2 cm in size. The need to have greater patient cooperation and the type of MRI contrast agents could explain the limitations of MRI in our study. A single typical imaging modality is sufficient to diagnose small HCC nodules in over 80 % of patients. We propose a CT scan as the first imaging modality and then proceeding to perform an ultrasound-guided liver biopsy in cases of inconclusive imaging.
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